Antimalarial drugs have been important tools in the fight against malaria and will be essential in the current effort to eliminate the disease.^[@ref1]−[@ref4]^ However, a major problem is the development of parasite resistance to the drugs, which threaten their effective use.^[@ref5]−[@ref9]^*Plasmodium falciparum* parasites resistant to antifolate drugs such as pyrimethamine (Pyr), an inhibitor of parasite dihydrofolate reductase (PfDHFR), and combinations of antifolate and sulfa drugs are widespread throughout malaria endemic regions.^[@ref10],[@ref11]^ Instead of abandoning PfDHFR as an antimalarial target, new approaches to develop antifolates effective against resistant parasites with mutated PfDHFR could be successful.^[@ref10],[@ref12]−[@ref15]^ The crystal structure of PfDHFR, which is joined with thymidylate synthase as a bifunctional enzyme, has been solved,^[@ref16]^ together with its counterpart in *P. vivax*.^[@ref17]^ These structures reveal features that explain the basis for mutation-induced resistance.^[@ref13],[@ref14]^ The structures of wild-type and mutant PfDHFRs cocomplexes have been solved with inhibitors, namely, WR99210, which can still inhibit mutant enzymes effectively,^[@ref18]^ and Pyr, to which binding has been compromised by PfDHFR mutations. Analysis of these structures has enabled target-based design of new inhibitors, some of which have very high efficacy and selectivity as antimalarial drugs.^[@ref15],[@ref19]^ These studies reveal the key S108N mutation in PfDHFR, which introduces a larger side-chain that sterically interferes with the binding of inhibitors with a rigid *p*-Cl-phenyl side chain such as Pyr and cycloguanil. Antifolate resistance is amplified when the S108N mutation is accompanied by additional mutations in the inhibitor binding region of PfDHFR including N51I, C59R, and I164L. Inhibitors such as WR99210 retain tight binding affinity with mutant PfDHFRs associated with Pyr resistance and retain efficacy against parasites with the corresponding mutant PfDHFRs. WR99210 and related compounds have flexible side-chains, which can avoid steric clash with the S108N side-chain. However, these flexible inhibitors can be rendered ineffective by further PfDHFR resistance mutations, as shown by a surrogate yeast^[@ref20]^ or bacterial system,^[@ref21],[@ref22]^ although the frequencies and the levels of resistance against WR99210 were lower than those for Pyr. Here, we present a new design of hybrid inhibitors, with both rigid and flexible side-chains in the same molecule as a combination that can reduce the emergence of resistance through mutations. An additional rationale for making such hybrid inhibitors is that there are conflicting requirements of PfDHFR in mutations conferring resistance to rigid (Pyr-like) and flexible (WR99210-like) inhibitors.^[@ref22]^

WR99210-resistant mutants isolated using a bacterial surrogate system are more sensitive to Pyr than Pyr-resistant mutants owing to the presence of wild-type PfDHFR residues S108, N51, C59, and I164.^[@ref21],[@ref22]^ In general, therefore, PfDHFRs can be divided into two series, namely, the "S108 series", which is sensitive to rigid inhibitors like Pyr but resistant to flexible inhibitors in combination with other mutations, and the "108N series" (or S108N series or N108 series^[@ref22]^), which is sensitive to flexible inhibitors but resistant to rigid inhibitors. We hypothesize that the combination of the two types of pharmacophore (rigid and flexible) in a single molecule should be effective against parasites with both types of PfDHFR. Specifically, the rigid pharmacophore should inhibit PfDHFRs in the S108 series, whereas the flexible pharmacophore should inhibit those in the 108N series. Furthermore, we hypothesize that mutations conferring resistance to hybrid inhibitors would be extremely limited owing to constraints on residues in the substrate/inhibitor binding region of PfDHFR.

In this Letter, we report the synthesis of hybrid inhibitors capable of inhibiting *P*. *falciparum* carrying either wild-type or multiple mutant DHFRs, and the modes of binding for these compounds. The hybrid inhibitors bind with similar affinities to both types of PfDHFR. Significantly, they bind in the active site of PfDHFRs in the expected manner, namely, binding with the rigid end to wild-type (S108) PfDHFR and with the flexible end to mutant (S108N) PfDHFR. The inhibitors show a low tendency to induce new antifolate-resistant mutants. Furthermore, in anticipation of further potential development as oral formulation, the 2,4-diaminopyrimidine scaffold was employed to take advantage of its *pK*~a~, which is suitable for oral bioavailability (*pK*~a~ 6--7), as previously rationalized in P218 development.^[@ref15]^ Hence, they should serve as good models for further development of oral antifolate antimalarials, which can forestall further development of mutation-induced resistance.

Results and Discussion {#sec2}
======================

Our previous works on the synthesis of DHFR inhibitors showed that P30 (a rigid diaminopyrimidine; Pyr-like with *m*-Cl substituent) and P65 (a flexible diaminopyrimidine; WR99210-like) are more effective inhibitors than Pyr.^[@ref15],[@ref23]^

In this study, we designed hybrid inhibitors through modification of the side chain of a rigid inhibitor at the *m*- or *p*-phenyl substituent, so that they carry a rigid and a flexible moiety at either end ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![Designs of inhibitors that can automatically modulate their binding modes to suit the catalytic sites which they encounter. (A) Structures of representative DHFR inhibitors. Pyr and P30 are rigid inhibitors, whereas P65 is a flexible inhibitor. (B) Our design of the dual binding mode DHFR hybrid inhibitors. The rigid part, represented by Pyr derivative, is joined with a flexible diaminopyrimidine moiety. (C) Structures of hybrid inhibitors synthesized in this study.](ml-2018-00389h_0001){#fig1}

In our design approach, hybrid compounds were prepared as outlined in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. Rigid diaminopyrimidines **2a**--**b** and the flexible diaminopyrimidine **3** were prepared according to methods modified from the previous reports ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A).^[@ref15],[@ref24]^ Mitsunobu reaction between compounds **2a**--**b** and **3** furnished the desired hybrid compounds **BT1** and **BT2** bearing two DHFR binding sites on opposite ends of the molecule. **BT1** consists of the rigid end linked at the *m*-phenyl substituent to the flexible end, whereas **BT2** has the rigid end linked at the *p*-phenyl substituent to the flexible end. For a hybrid bearing rigid ends on both sides of the molecule with a flexible five-atom linker, a condensation reaction of enol-ether of compound **4** with guanidine was performed to yield the desired hybrid **BT3** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B). In this study, compounds **BT2S** and **BT3S**, which are hydrochloride salt forms of **BT2** and **BT3**, respectively, were also prepared to give compounds with greater solubility for biological testing.

![Synthesis of Hybrid Inhibitors: (A) Rigid--Flexible Hybrid and (B) Rigid--Rigid Hybrid\
Reagents and conditions: (a) CH~2~N~2~, dioxane-MeOH; (b) guanidine, DMSO-MeOH, 90--100 °C; (c) cyclohexene, Pd/C, 65 °C; (d) Ph~3~P, DIAD, DMF, rt; (e) HCl, H~2~O.](ml-2018-00389h_0004){#sch1}

We determined the inhibition constants, anti-Plasmodial activities, and toxicities against mammalian (Vero) cells of the hybrid inhibitors. [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} shows the inhibition constants (*K*~i~) against PfDHFR enzymes of the hybrid inhibitors, together with Pyr, P30, and P65 as comparators. **BT1** shows very high affinities for both wild-type and mutant PfDHFRs, with much higher *K*~i~ values for human DHFR (hDHFR), giving high *K*~i~ ratio (selectivity) value, as compared with P30 and P65. However, **BT2** and **BT2S** show lower affinities for PfDHFRs and hDHFR, giving lower selectivity. In contrast, Pyr shows weak binding with the mutant enzymes, whereas P30 shows stronger binding with both wild-type and mutant enzymes. However, these compounds gave very low selectivity values. Unexpectedly, the bi-rigid **BT3S** also has high affinities for all PfDHFRs with high selectivity.

###### Inhibition Constants (*K*~i~) of the Compounds against DHFR Enzymes

                                             *K*~i~ PfDHFR[e](#t1fn5){ref-type="table-fn"} (nM, ± SD)                                                                                                                                                                                                                                         
  ------------------------------------------ ---------------------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------
  Pyr                                        0.60 ± 0.20[a](#t1fn1){ref-type="table-fn"}                53.9 ± 6.5[a](#t1fn1){ref-type="table-fn"}    67.1 ± 4.2[b](#t1fn2){ref-type="table-fn"}    112 ± 17[b](#t1fn2){ref-type="table-fn"}      390 ± 160[b](#t1fn2){ref-type="table-fn"}     28.2 ± 2.5[c](#t1fn3){ref-type="table-fn"}    0.07
  P30                                        0.80 ± 0.10[a](#t1fn1){ref-type="table-fn"}                1.40 ± 0.00[a](#t1fn1){ref-type="table-fn"}   2.10 ± 0.22[b](#t1fn2){ref-type="table-fn"}   2.71 ± 0.43[b](#t1fn2){ref-type="table-fn"}   3.30 ± 0.40[b](#t1fn2){ref-type="table-fn"}   1.60 ± 0.20[c](#t1fn3){ref-type="table-fn"}   0.5
  P65                                        0.49 ± 0.10                                                3.15 ± 0.13                                   2.61 ± 0.22                                   4.21 ± 0.23                                   5.59 ± 0.10[d](#t1fn4){ref-type="table-fn"}   47.6 ± 4.0                                    8.5
  **BT1**                                    0.44 ± 0.04                                                0.53 ± 0.07                                   0.71 ± 0.14                                   1.25 ± 0.10                                   2.32 ± 0.24                                   22.5 ± 2.9                                    9.7
  **BT2**[f](#t1fn6){ref-type="table-fn"}    0.35 ± 0.02                                                1.03 ± 0.12                                   1.00 ± 0.15                                   6.32 ± 0.87                                   6.96 ± 0.91                                   18.1 ± 1.3                                    2.6
  **BT2S**[g](#t1fn7){ref-type="table-fn"}   0.31 ± 0.05                                                1.10 ± 0.19                                   0.74 ± 0.09                                   5.72 ± 0.90                                   5.8 ± 1.5                                     20.2 ± 3.3                                    3.5
  **BT3S**[g](#t1fn7){ref-type="table-fn"}   0.40 ± 0.03                                                1.34 ± 0.23                                   1.35 ± 0.27                                   2.66 ± 0.35                                   4.1 ± 1.2                                     33.6 ± 10.6                                   8.1

Data from ref ([@ref23]).

Data from ref ([@ref25]).

Data from ref ([@ref26]).

Data from ref ([@ref15]).

Parentheses refer to PfDHFR haplotypes for residues 51, 59, 108, and 164.

Maximum soluble concentration = 1 μM.

Salt forms of **BT2** and **BT3** were used due to their higher solubilities.

[Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} shows the anti-Plasmodial activities (IC~50~) and toxicities against mammalian (Vero) cells of the inhibitors. As anticipated from the *K*~i~ values, **BT1** shows good IC~50~ (\<5 μM) against both wild-type and Pyr-resistant mutant *P. falciparum*. The corresponding IC~50~ value is higher against Vero cells, which translates to moderate to high selectivity. **BT2S** shows lower IC~50~ than **BT1** for wild-type; however, it has comparable IC~50~ against mutant parasite and selectivity to P65, but with lower IC~50~ than **BT1**. Interestingly, the bi-rigid inhibitor **BT3S** shows good IC~50~ against both wild-type and mutant parasite with better selectivity than **BT1** and **BT2S**. In contrast, P30 and P65 show markedly lower selectivity owing to either poor inhibition of mutant parasite strains or similar inhibition of parasites and Vero mammalian cells.

###### Anti-Plasmodial Activity (IC~50~) against *P. falciparum* Carrying Wild-Type or Mutant DHFR and Cytotoxicity against Mammalian (Vero) Cells of the Compounds

                                             IC~50~*P. falciparum*[e](#t2fn5){ref-type="table-fn"} (μM, ± SD)                                                                                                                                                                                                                             
  ------------------------------------------ ------------------------------------------------------------------ --------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------- ----------------------------------- ------------------------------------
  Pyr                                        0.08 ± 0.01[a](#t2fn1){ref-type="table-fn"}                        30.9 ± 8.4[a](#t2fn1){ref-type="table-fn"}    73.5 ± 8.5[b](#t2fn2){ref-type="table-fn"}    42 ± 15[b](#t2fn2){ref-type="table-fn"}       \>100[b](#t2fn2){ref-type="table-fn"}       \>100                               NA[c](#t2fn3){ref-type="table-fn"}
  P30                                        0.42 ± 0.10[a](#t2fn1){ref-type="table-fn"}                        1.31 ± 0.45[a](#t2fn1){ref-type="table-fn"}   3.94 ± 0.80[b](#t2fn2){ref-type="table-fn"}   2.53 ± 0.38[b](#t2fn2){ref-type="table-fn"}   9.1 ± 2.8[b](#t2fn2){ref-type="table-fn"}   7[a](#t2fn1){ref-type="table-fn"}   0.8
  P65                                        0.23 ± 0.07[d](#t2fn4){ref-type="table-fn"}                        1.92 ± 0.53                                   2.27 ± 0.65                                   4.4 ± 2.1                                     3.5 ± 1.6[d](#t2fn4){ref-type="table-fn"}   4.03 ± 0.41                         1.2
  **BT1**                                    0.29 ± 0.05                                                        0.22 ± 0.06                                   0.25 ± 0.05                                   0.51 ± 0.08                                   1.72 ± 0.69                                 5.94 ± 0.65                         3.4
  **BT2S**[f](#t2fn6){ref-type="table-fn"}   0.063 ± 0.014                                                      1.84 ± 0.31                                   2.35 ± 0.10                                   3.95 ± 0.36                                   4.40 ± 0.71                                 6.3 ± 1.5                           1.4
  **BT3S**[f](#t2fn6){ref-type="table-fn"}   0.035 ± 0.0033                                                     0.33 ± 0.038                                  0.30 ± 0.03                                   0.31 ± 0.02                                   0.33 ± 0.023                                2.53 ± 0.44                         7.7

Data from ref ([@ref23]).

Data from ref ([@ref25]).

Not applicable.

Data from ref ([@ref15]).

Parentheses refer to PfDHFR haplotypes in *P. falciparum* strains for residues 51, 59, 108, and 164.

Salt forms of **BT2** and **BT3** were used due to their higher solubility.

We assessed the potential of PfDHFR variants conferring resistance to **BT1** using a bacterial surrogate system. From a library of 1.5 × 10^5^ PfDHFR variants, **BT1**-resistant cells were obtained. Fourteen independent **BT1**-resistant colonies were characterized by DNA sequencing, which showed novel resistance mutations K97N, S108T, and E199V in addition to the Pyr-resistant mutations N51I, C59R, and I164L. However, all **BT1**-resistant mutants shared the same haplotype (combination of mutations) of IRNTLV, in contrast with the wild-type NCKSIE and quadruple mutant IRKNLE haplotypes. From these data, we infer that the diversity of **BT1**-resistant PfDHFR variants is much lower than that of variants resistant to rigid or flexible antifolates, each with 12 different haplotypes.^[@ref22]^ However, the diversity of PfDHFR resistance mutations in parasites could be affected by other factors, such as GTP cyclohydrolase gene copy number,^[@ref27]^ which are not modeled in the bacterial surrogate.

Cocrystal structures of the hybrid inhibitors with the enzymes were investigated. According to the binding modes of wild-type and mutant PfDHFRs with rigid and flexible pyrimidine inhibitors,^[@ref16]^ the rigid end of **BT1** with a *m*-phenyl substituent on the pyrimidine nucleus would be expected to bind preferentially to the active site pocket containing S108 of the wild-type PfDHFR with no steric hindrance. However, it was possible that the bulky *p*-phenyl substituent of **BT2** might encounter steric clash even with S108, and **BT2** might preferentially bind to the wild-type active site with the flexible end. However, the flexible ends of both **BT1** and **BT2** should bind preferentially to the active site of mutant PfDHFR containing the bulky S108N. Notably, **BT3** can only bind to the active sites of wild-type and mutant PfDHFR in the same way. To investigate the effects and the interaction mode of the three inhibitors to PfDHFR enzyme, we determined **BT1**, **BT2**, and **BT3** cocrystal structures of PfDHFR-TS, both wild-type and quadruple mutant DHFR domains at 2.2--2.38 and 2.38--2.6 Å resolutions, respectively ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and Table S1 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00389/suppl_file/ml8b00389_si_001.pdf)). Moreover, **BT1** and **BT2** cocrystal structures with hDHFR were determined in order to visualize the difference in the binding modes of the hybrid inhibitors (see details in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00389/suppl_file/ml8b00389_si_001.pdf)).

![Inhibition modes of hybrid inhibitors in PfDHFR. Detailed interactions of (A) **BT1**, (B) **BT2**, and (C) **BT3** with wild-type PfDHFR, quadruple mutant PfDHFR, and superposition of wild-type and quadruple mutant PfDHFRs. Displacement of NADPH was observed in quadruple mutant due to steric clash with S108N upon binding of **BT3**. Inhibitors and key amino acids are shown as a stick model. Important interactions are highlighted as dashed lines in black, and π--π interaction is drawn as a double dashed line.](ml-2018-00389h_0002){#fig2}

As expected, **BT1** showed distinctive binding modes between wild-type and quadruple mutant PfDHFRs ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). It binds to the wild-type enzyme with the rigid end in the active site, through the pyrimidine moiety interacting with D54 and the rigid phenyl in the vicinity of S108. In contrast, the flexible end of **BT1** binds to the quadruple mutant enzyme at D54, with the flexible alkoxy group avoiding steric clash with S108N in close proximity (3.4 Å). The nicotinamide moiety of NADPH was not perturbed by binding of **BT1** and the pyrimidine core of the rigid end formed π--π interaction with F116. **BT1** with *m*-phenyl substitution is therefore a potentially good template for inhibitors, which would forestall further resistance mutations in both the S108 and 108N series.

Interestingly, in contrast to the **BT1** structures, **BT2** binds to both wild-type and quadruple mutant PfDHFR with its flexible ends ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). An explanation for this finding is that in the wild-type enzyme, although there is no steric clash of the rigid end at S108, the *p*-substituted phenyl moiety would collide with the hydrophobic pocket of residues 111--116 if the rigid end of **BT2** was docked at 54. For the quadruple mutant enzyme, the flexible end can avoid the steric clash with S108N and is preferred to the rigid end at D54 site, while the rigid end of the molecule caused some conformational adjustment of the enzyme ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B).

As for compound **BT3**, comprising rigid moieties on both ends, its good binding to quadruple mutant as well as wild-type PfDHFR was at first surprising. However, the high affinity binding can be explained by the X-ray structures of **BT3** complexed with both wild-type and quadruple mutant PfDHFR, which showed well adapted accommodation of the active sites to **BT3** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C). The side chain of S108N greatly swung away from the active pocket to make room for accommodation of **BT3** as compared to **BT1** and **BT2**. Interestingly, the binding geometry of **BT3** is very similar for both wild-type and quadruple mutant PfDHFR; however, in the PfDHFR quadruple mutant, **BT3** binding causes a significant displacement of the nicotinamide moiety, resulting from a severe steric clash ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). From these data, we infer that the enhanced inhibition of **BT3** in PfDHFR quadruple mutant occurs through displacement of NADPH cofactor, which is insignificant in the wild-type enzyme. A high temperature factor of NADPH was observed in monomer A of quadruple mutant PfDHFR, whereas in monomer B NADPH could not be fully presented owing to very weak electron density. It is noteworthy that no or very little NADPH perturbation was observed where the flexible part of the compounds was docked at D54. Therefore, the displacement of the nicotinamide ring of NADPH is important for inhibition of the PfDHFR quadruple mutant by **BT3**.

![Superposition of cocomplex **BT1**, **BT2**, and **BT3** structures of PfDHFRs. (A) Wild-type PfDHFR. (B) Quadruple mutant PfDHFR. The nicotinamide ring of NADPH was perturbed by the binding of the hybrid inhibitors to different levels in quadruple mutant PfDHFR structures, while insignificant displacement of NADPH occurred in wild-type. The most severe perturbation of the NADPH was observed with the binding of **BT3**, which coincided with the displacement of S108N side chain.](ml-2018-00389h_0003){#fig3}

In conclusion, hybrid compounds such as **BT1** with rigid and flexible pharmacophores in the same molecule can bind with high affinity to either wild-type/S108 series or quadruple mutant/108N series PfDHFR in the expected manner, consequently with favorable IC~50~ and selectivity. Significantly, the diversity of mutants resistant to **BT1** is extremely limited, in accordance with our prediction from our earlier finding^[@ref22]^ that there are conflicting requirements for resistance mutations against rigid and flexible inhibitors that tightly constrain resistance mutations against hybrid compounds. It is noted that another hybrid compound, **BT2**, binds both wild-type and mutant PfDHFR with the flexible end. Yet another compound, **BT3**, which is rigid at both ends, binds both wild-type and mutant PfDHFR with good affinities. These apparent anomalies are, however, fully explained by the X-ray structures of the complexes, which show conformational changes of the enzyme to accommodate the inhibitor. The high antimalarial activity of **BT1** and, importantly, its ability to forestall resistance mutations, makes it a good template for further design and synthesis of antifolates, which are less vulnerable to resistance. This family of rigid-flexible hybrid compounds can be added to the list of new antifolates such as P218 with good activity against pyrimethamine-resistant *P. falciparum*.^[@ref15]^

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.8b00389](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.8b00389).Result of cocrystal structures of hybrid inhibitors with hDHFR; materials and methods; Figure S1 and Tables S1 and S2 ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.8b00389/suppl_file/ml8b00389_si_001.pdf))
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The atomic coordinates and structure factor amplitudes have been deposited in the Protein Data Bank: PfDHFR-TS with accession codes 6A2K (TM4-**BT1**), 6A2L (V1/S-**BT1**), 6A2M (TM4-**BT2**), 6A2N (V1/S-**BT2**), 6A2O (TM4-**BT3**), and 6A2P (V1/S-**BT3**), and hDHFR with accession codes 6A7C (**BT1**) and 6A7E (**BT2**).
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PfDHFR

:   *Plasmodium falciparum* dihydrofolate reductase

hDHFR

:   human dihydrofolate reductase

PfDHFR-TS

:   *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase

Pyr

:   pyrimethamine

DIAD

:   diisopropyl azodicarboxylate
